丁苯酞联合阿托伐他汀对急性脑梗死患者神经功能及炎症因子IL-6、CRP的影响
|
摘要
目的:探讨丁苯酞联合阿托伐他汀对急性脑梗死患者神经功能的影响。方法:选取2017年7月至2018年6月期间我院收治的92例急性脑梗死患者,随机分为对照组和联合组,每组46例。对照组在常规治疗(溶栓、抗血小板聚集、改善循环、营养脑细胞等)基础上给予阿托伐他汀治疗,联合组在对照组基础上增加丁苯酞注射液治疗,比较两组治疗效果,并分别于用药治疗前和治疗14 d后采集静脉血,检测炎症因子IL-6、CRP水平,并对比两组不良反应发生情况。结果:联合组治疗总有效率较对照组高;治疗后,联合组NIHSS评分、IL-6及CRP水平明显低于治疗前与对照组,上述差异均具有统计学意义(P <0. 05)。联合组不良反应总发生率略高于对照组,但差异无统计学意义(P> 0. 05)。结论:丁苯酞联合阿托伐他汀治疗急性脑梗死安全有效,可明显改善患者神经功能,减轻机体炎症反应。
Objective: To investigate the influence of butyphthalide combined with atorvastatin on nerve function in patients with acute cerebral infarction. Methods: 92 patients with acute cerebral infarction who admitted in the hospital from July 2017 to June 2018 were selected as the subjects. All patients were randomly divided into control group and combined group,with 46 cases in each group. Control group was given atorvastatin based on routine treatment( thrombolysis,anti-platelet aggregation,improving circulation,nourishing brain cell),while combined group was treated with butyphthalide injection based on control group. The curative effects of two groups were compared. The venous blood was taken before treatment and after treatment for 14 d,the levels of IL-6 and CRP were detected,and the adverse reactions were compared between the two groups. Results: The total effective rate of combined group was higher than that of control group; After treatment,the NIHSS score,IL-6 and CRP in combined group were lower than those before treatment and control group,and the above differences were statistically significant( P < 0. 05). The total incidence of adverse reactions in combined group was slightly higher than that in control group,but the difference was not statistically significant( P > 0. 05). Conclusion: Butyphthalide combined with atorvastatin in treatment of patients with acute cerebral infarction is safe and effective,which can significantly improve nerve function and reduce inflammatory response.
Objective: To investigate the influence of butyphthalide combined with atorvastatin on nerve function in patients with acute cerebral infarction. Methods: 92 patients with acute cerebral infarction who admitted in the hospital from July 2017 to June 2018 were selected as the subjects. All patients were randomly divided into control group and combined group,with 46 cases in each group. Control group was given atorvastatin based on routine treatment( thrombolysis,anti-platelet aggregation,improving circulation,nourishing brain cell),while combined group was treated with butyphthalide injection based on control group. The curative effects of two groups were compared. The venous blood was taken before treatment and after treatment for 14 d,the levels of IL-6 and CRP were detected,and the adverse reactions were compared between the two groups. Results: The total effective rate of combined group was higher than that of control group; After treatment,the NIHSS score,IL-6 and CRP in combined group were lower than those before treatment and control group,and the above differences were statistically significant( P < 0. 05). The total incidence of adverse reactions in combined group was slightly higher than that in control group,but the difference was not statistically significant( P > 0. 05). Conclusion: Butyphthalide combined with atorvastatin in treatment of patients with acute cerebral infarction is safe and effective,which can significantly improve nerve function and reduce inflammatory response.
引文
[1]宫丽,曹雄彬,卢振,等.急性脑梗死患者不同剂量阿托伐他汀治疗后血清脂肪因子水平与脑功能恢复的关系研究[J].浙江医学,2010,40(2):148-151.
[2]乔宏泉,张亮亮,彭军华.阿托伐他汀钙与阿司匹林联合治疗对急性脑梗死患者血脂水平及神经功能的影响[J].中国医院用药评价与分析,2018,18(5):641-643.
[3]王鹏,孙中武,王本孝,等.强化阿托伐他汀治疗对老年急性脑梗死患者血清ox-LDL、CRP水平及神经功能的影响[J].中国老年学杂志,2018,38(5):1049-1051.
[4]王娟,郭岩.瑞舒伐他汀和阿托伐他汀治疗急性脑梗死疗效及对患者神经功能影响比较研究[J].陕西医学杂志,2018,47(10):1331-1333.
[5]陈群,罗勇,范军伟,等.阿托伐他汀联合丁苯酞氯化钠注射液治疗的ACI患者血脂、氧化应激指标、脂联素水平观察[J].山东医药,2018,58(11):56-58.
[6] Margag L. Genetic modulation of plasma fibrinogen fibrinogen concentrations:Possible importance of interleukin-6[J]. Thromb Thromboylysis,2000,3(1):51-56.
[7]张东风.丁苯酞联合阿托伐他汀对急性脑梗死患者血流动力学及血清SOD、GSH-Px、NO水平的影响[J].临床药物治疗杂志,2018,16(3):37-41.
[8] Qiuyun Tu,Hui Cao,Wei Zhong,et al. Atorvastatin protects against cerebralischemia/reperfusion injury through anti-inflammatory and antioxidant effects[J]. Neural Regen Res,2014,9(3):268-275.
[9]李强,田文艳,陈立英,等.丁苯酞对急性脑梗死患者血管内皮生长因子、肿瘤坏死因子α及神经功能的影响[J].医学综述,2017,23(5):1001-1005.
[10]牛慧艳,张占强,王海,等.丁苯酞软胶囊联合阿托伐他汀钙对急性脑梗死患者血清IL-6、IL-8和动脉粥样硬化斑块的影响[J].现代中西医结合杂志,2017,26(27):2968-2971.
[11]陈颖,朱新岭,杨君君,等.丁苯酞联合较高剂量阿托伐他汀治疗急性脑梗死临床观察[J].中国药师,2018,21(7):1227-1230.
[2]乔宏泉,张亮亮,彭军华.阿托伐他汀钙与阿司匹林联合治疗对急性脑梗死患者血脂水平及神经功能的影响[J].中国医院用药评价与分析,2018,18(5):641-643.
[3]王鹏,孙中武,王本孝,等.强化阿托伐他汀治疗对老年急性脑梗死患者血清ox-LDL、CRP水平及神经功能的影响[J].中国老年学杂志,2018,38(5):1049-1051.
[4]王娟,郭岩.瑞舒伐他汀和阿托伐他汀治疗急性脑梗死疗效及对患者神经功能影响比较研究[J].陕西医学杂志,2018,47(10):1331-1333.
[5]陈群,罗勇,范军伟,等.阿托伐他汀联合丁苯酞氯化钠注射液治疗的ACI患者血脂、氧化应激指标、脂联素水平观察[J].山东医药,2018,58(11):56-58.
[6] Margag L. Genetic modulation of plasma fibrinogen fibrinogen concentrations:Possible importance of interleukin-6[J]. Thromb Thromboylysis,2000,3(1):51-56.
[7]张东风.丁苯酞联合阿托伐他汀对急性脑梗死患者血流动力学及血清SOD、GSH-Px、NO水平的影响[J].临床药物治疗杂志,2018,16(3):37-41.
[8] Qiuyun Tu,Hui Cao,Wei Zhong,et al. Atorvastatin protects against cerebralischemia/reperfusion injury through anti-inflammatory and antioxidant effects[J]. Neural Regen Res,2014,9(3):268-275.
[9]李强,田文艳,陈立英,等.丁苯酞对急性脑梗死患者血管内皮生长因子、肿瘤坏死因子α及神经功能的影响[J].医学综述,2017,23(5):1001-1005.
[10]牛慧艳,张占强,王海,等.丁苯酞软胶囊联合阿托伐他汀钙对急性脑梗死患者血清IL-6、IL-8和动脉粥样硬化斑块的影响[J].现代中西医结合杂志,2017,26(27):2968-2971.
[11]陈颖,朱新岭,杨君君,等.丁苯酞联合较高剂量阿托伐他汀治疗急性脑梗死临床观察[J].中国药师,2018,21(7):1227-1230.